PMID- 12464650
OWN - NLM
STAT- MEDLINE
DCOM- 20030110
LR  - 20221207
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 94
IP  - 23
DP  - 2002 Dec 4
TI  - Association of HLA class I and II alleles and extended haplotypes with 
      nasopharyngeal carcinoma in Taiwan.
PG  - 1780-9
AB  - BACKGROUND: Nasopharyngeal carcinoma (NPC), which occurs at a disproportionately 
      high rate among Chinese individuals, is associated with Epstein-Barr virus (EBV). 
      Human leukocyte antigen (HLA) polymorphisms appear to play a role in NPC, because 
      they are essential in the immune response to viruses. We used high-resolution HLA 
      genotyping in a case-control study in Taiwan to systematically evaluate the 
      association between various HLA alleles and NPC. METHODS: We matched 366 NPC case 
      patients to 318 control subjects by age, sex, and geographic residence. 
      Participants were interviewed and provided blood samples for genotyping. 
      High-resolution (polymerase chain reaction-based) genotyping of HLA class I (A 
      and B) and II (DRB1, DQA1, DQB1, and DPB1) genes was performed in two phases. In 
      phase I, 210 case patients and 183 control subjects were completely genotyped. In 
      phase II, alleles associated with NPC in the phase I analysis were evaluated in 
      another 156 case patients and 135 control subjects. Extended haplotypes were 
      inferred. RESULTS: We found a consistent association between HLA-A*0207 (common 
      among Chinese but not among Caucasians) and NPC (odds ratio [OR] = 2.3, 95% 
      confidence interval [CI] = 1.5 to 3.5) but not between HLA-A*0201 (most common 
      HLA-A2 allele in Caucasians) and NPC (OR = 0.79, 95% CI = 0.55 to 1.2). 
      Individuals with HLA-B*4601, which is in linkage disequilibrium with HLA-A*0207, 
      had an increased risk for NPC (OR = 1.8, 95% CI = 1.2 to 2.5) as did individuals 
      with HLA-A*0207 and HLA-B*4601 (OR = 2.8, 95% CI = 1.7 to 4.4). Individuals 
      homozygous for HLA-A*1101 had decreased risks for NPC (OR = 0.24, 95% CI = 0.13 
      to 0.46). The extended haplotype 
      HLA-A*3303-B*5801/2-DRB1*0301-DQB1*0201/2-DPB1*0401, specific to this ethnic 
      group, was associated with a statistically significantly increased risk for NPC 
      (OR = 2.6, 95% CI = 1.1 to 6.4). CONCLUSIONS: The restriction of the association 
      of HLA-A2 with NPC to HLA-A*0207 probably explains previously observed 
      associations of HLA-A2 with NPC among Chinese but not Caucasians. The extended 
      haplotypes associated with NPC might, in part, explain the higher rates of NPC in 
      this ethnic group.
FAU - Hildesheim, Allan
AU  - Hildesheim A
AD  - Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, 
      National Cancer Institute, 6120 Executive Boulevard, Rm. 7062, Rockville, MD 
      20852, USA. Hildesha@exchange.nih.gov
FAU - Apple, Raymond J
AU  - Apple RJ
FAU - Chen, Chien-Jen
AU  - Chen CJ
FAU - Wang, Sophia S
AU  - Wang SS
FAU - Cheng, Yu-Juen
AU  - Cheng YJ
FAU - Klitz, William
AU  - Klitz W
FAU - Mack, Steven J
AU  - Mack SJ
FAU - Chen, I-How
AU  - Chen IH
FAU - Hsu, Mow-Ming
AU  - Hsu MM
FAU - Yang, Czau-Siung
AU  - Yang CS
FAU - Brinton, Louise A
AU  - Brinton LA
FAU - Levine, Paul H
AU  - Levine PH
FAU - Erlich, Henry A
AU  - Erlich HA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DR Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Alleles
MH  - Asian People/*genetics
MH  - Carcinoma/*genetics/immunology
MH  - Case-Control Studies
MH  - Female
MH  - *Genes, MHC Class I
MH  - *Genes, MHC Class II
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/genetics
MH  - HLA-DP Antigens/genetics
MH  - HLA-DQ Antigens/genetics
MH  - HLA-DR Antigens/genetics
MH  - Haplotypes
MH  - Humans
MH  - Linkage Disequilibrium
MH  - Male
MH  - Middle Aged
MH  - Nasopharyngeal Neoplasms/*genetics/immunology
MH  - Odds Ratio
MH  - Taiwan
EDAT- 2002/12/05 04:00
MHDA- 2003/01/11 04:00
CRDT- 2002/12/05 04:00
PHST- 2002/12/05 04:00 [pubmed]
PHST- 2003/01/11 04:00 [medline]
PHST- 2002/12/05 04:00 [entrez]
AID - 10.1093/jnci/94.23.1780 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2002 Dec 4;94(23):1780-9. doi: 10.1093/jnci/94.23.1780.